Nature Medicine, Published online: 29 October 2026; doi:10.1038/s41591-026-04723-w
A 5-year secondary analysis of the phase 2 PHERGain trial supports the clinical utility of a PET-guided adaptive strategy for treatment de-escalation in HER2-positive early breast cancer and provides circulating tumor DNA insights that could inform further treatment approaches.
